Differences Between Changes in Serum Thyrotropin-Binding Inhibitory Antibodies and Thyroid-Stimulating Antibodies in the Course of Antithyroid Drug Therapy for Graves' Disease

There has recently been controversy regarding whether the measurement of thyrotropin-binding inhibitory antibodies (TBIAb) is useful in the management of Graves' disease. Another method of assessing Graves' disease by measuring adenylate cyclase activity in thyroid cells, known as thyroid-stimulating antibodies (TSAb), differs from TBIAb not only in terms of assay but also in immunoglobulin type a…